404 A BONE SCAN INDEX TO QUANTIFY THE EXTENT OF SKELETAL INVOLVEMENT BY TUMOR CAN BE USED TO PREDICT SURVIVAL IN PROSTATE CANCER PATIENTS (2010)

You have accessJournal of UrologyProstate Cancer: Staging III1 Apr 2010404 A BONE SCAN INDEX TO QUANTIFY THE EXTENT OF SKELETAL INVOLVEMENT BY TUMOR CAN BE USED TO PREDICT SURVIVAL IN PROSTATE CANCER PATIENTS David Ulmert, Thomas Björk, Anders Bjartell, Hans Lilja, Peter Höglund, Mattias Ohlsson, and Lars Edenbrandt David UlmertDavid Ulmert Malmö, Sweden More articles by this author , Thomas BjörkThomas Björk Malmö, Sweden More articles by this author , Anders BjartellAnders Bjartell Malmö, Sweden More articles by this author , Hans LiljaHans Lilja New York, NY More articles by this author , Peter HöglundPeter Höglund Lund, Sweden More articles by this author , Mattias OhlssonMattias Ohlsson Lund, Sweden More articles by this author , and Lars EdenbrandtLars Edenbrandt Malmö, Sweden More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.473AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The extent of bone involvement in patients with prostate cancer (PCa) has shown to be prognostic for survival, but there has not been a clinically useful quantification method available for routine practice. We recently developed a completely automated method for quantification of whole-body bone scans based on the bone scan index (BSI) method as presented by the Memorial Sloan-Kettering Cancer Center research group. The objective with this study was to evaluate the value of the BSI in relation to prostate-specific antigen (PSA) to predict survival in patients with PCa. METHODS This retrospective study was based on PCa patients in two large population cohorts with extensive follow-up; the Malmö Preventive Medicine Cohort and the Malmö Diet and Cancer cohort. 1801 of the 26,656 men that participated in either one or both of these population studies were diagnosed with PCa up to 2007/01/01. Patient charts were retrieved for 75% of the patients. A digitally stored whole-body bone scan and a PSA analysis obtained at the time of diagnosis was found in 392 of these patients. The software package EXIN bone (EXINI diagnostics AB, Lund, Sweden) was used to calculate BSI. Cause of death was obtained from the Swedish board of health and welfare. A Cox proportional hazards regression model was used to evaluate the BSI and the PSA values. RESULTS The cause of death was PCa in 49 of the 392 patients. The median follow-up time from bone scan to endpoint was 6.5 years. When BSI and PSA were considered in single-variable analysis, both parameters were significantly associated with survival (p<0.001). BSI remained significant (p<0.001), but PSA was no longer associated with survival (p=0.63) if both BSI and PSA were included in a multi-variable analysis. Associations between BSI/PSA and survival using the Kaplan-Meier method are shown in the Figure. CONCLUSIONS BSI calculated using a completely automated method can be used to predict survival in PCa patients. This method for quantification of bone scans could be used as an additional method for monitoring this patient group. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e160 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information David Ulmert Malmö, Sweden More articles by this author Thomas Björk Malmö, Sweden More articles by this author Anders Bjartell Malmö, Sweden More articles by this author Hans Lilja New York, NY More articles by this author Peter Höglund Lund, Sweden More articles by this author Mattias Ohlsson Lund, Sweden More articles by this author Lars Edenbrandt Malmö, Sweden More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...